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Abstract
Background: Peutz–Jeghers syndrome (PJS) is a rare autosomal dominant inherited disorder characterized by
gastrointestinal (GI) hamartomatous polyps, mucocutaneous hyperpigmentation, and an increased risk of cancer.
Mutations in the serine–threonine kinase 11 gene (SKT11) are the major cause of PJS.
Case presentation: Blood samples were collected from six PJS families including eight patients. Mutation
screening of STK11 gene was performed in these six families by Sanger sequencing and multiplex ligation-
dependent probe amplification (MLPA) assay. Three novel mutations (c.721G > C, c.645_726del82, and del(exon2–5))
and three recurrent mutations (c.752G > A, c.545 T > C and del(exon1)) in STK11 were detected in six Chinese PJS
families. Genotype-phenotype correlations suggested that truncating mutations trend to result in severe
complications.
Conclusion: These findings broaden the mutation spectrum of the STK11 gene and would help clinicians and
genetic counselors provide better clinical surveillance for PJS patients, especially for ones carrying truncating
mutation.
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Background
Peutz–Jeghers syndrome (PJS) is a rare autosomal dom-
inant inherited disorder characterized by gastrointestinal
(GI) hamartomatous polyps, mucocutaneous hyperpig-
mentation of the lips, buccal mucosa, and digits. PJS
polyps often lead to severe complications, such as intus-
susceptions and intestinal obstruction. Beyond these
symptoms, PJS patients also have an increased risk of
cancer at multiple sites, including the GI tract, breast,
ovary, testis, and lung [1]. The cumulative lifetime risk is
20, 43, 71, and 89 % at ages 40, 50, 60 and 65 years, re-
spectively [2].
Germline mutations in the serine–threonine kinase 11
(STK11) gene on chromosome 19p13.3 were identified
as a cause of PJS in 1998 [3, 4]. The gene, 23 kb in size,
consists of nine coding exon and one non-coding exon
and encodes a 433-amino acid protein, which consists of
three domains: the N-terminal non-catalytic domain, the
catalytic kinase domain, and the C-terminal non-
catalytic regulatory domain. This protein which also acts
as a tumor suppressor factor is involved in cell growth,
cell polarity, and energy metabolism and plays a pleio-
tropic role in tumorigenesis [5]. Recent studies showed
that mutations in STK11 can be found in 57–88 % of
PJS cases, including point mutations and large genomic
deletions/insertions/duplications [6–9].
In this study, we report three novel mutations and
three recurrent mutations in STK11, which were de-
tected in six Chinese PJS families by Sanger sequencing
and the multiplex ligation-dependent probe amplifica-
tion (MLPA) assay.* Correspondence: liangdesheng@sklmg.edu.cn; wulingqian@sklmg.edu.cn1The State Key Laboratory of Medical Genetics, Central South University, 110
Xiangya Road, Changsha, Hunan 410078, China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




Eight PJS patients from six unrelated Chinese families
were enrolled at the Genetics Clinic of the State Key
Laboratory of Medical Genetics (SKLMG). Clinical
diagnosis for PJS was based on no less than two of
these three criteria: characteristic mucocutaneous
pigmentation, hamartomatous polyps, and a family
history. 100 healthy Chinese individuals (age range
from 17 to 40 years, average 22 years) were recruited
as controls. Informed consent for this investigation
was obtained from all participating PJS patients and
parents, and the principles outlined in the Declaration
of Helsinki were followed.
Mutation screening and MLPA assay
Genomic DNA was extracted from peripheral blood by
the phenol–chloroform method. The entire coding re-
gion and intron–exon boundaries of STK11 (RefSeq
NM_000455) were analyzed by direct Sanger sequencing.
Functional signification of novel mutations was pre-
dicted by two online software programs, PolyPhen-2
software (http://genetics.bwh.harvard.edu/pph2) and
Swiss-Model software (http://swissmodel.expasy.org).
The MLPA test kit (SALSA P101-B1 STK11; MRC-
Holland, Amsterdam, The Netherlands) was used to de-
tect large genomic deletion/duplication of STK11 in
samples with negative Sanger sequencing results. All op-
erations were conducted using an ABI 3100 genetic
analyzer (Applied Biosystems, Carlsbad, CA, USA) fol-
lowing the manufacturer’s recommendations. This ex-
periment was done in triplicates.
Case presentation
A total of eight patients (2 females and 6 males) from
six unrelated families were involved in this study
(Table 1). Three of these families (family 3, 4, and 5)
showed autosomal dominant pattern and the remaining
families (family 1, 2, and 6) are sporadic (Fig. 1a). The
patients’ age at STK11 gene testing ranged from 7 to
38 years old. Five probands in these families underwent
the first loparotomy or polypectomy at an earlier age
(from 7 to 22 years old), due to abdominal pain or
hemafecia. Three out of these patients suffered from
some severe complications, intussusceptions and intes-
tinal obstruction. None of these patients enrolled in this
study had developed cancer up to the test age except the
patient 101 with colonic adenoma. This may be due to a
young age (7–45 years old). Detail clinical information is
showed in Table 1.
Results
Direct sequencing of STK11 gene revealed two recurrent
mutation (c.525 T > C and c.752G > A) and two novel
mutations (c.721G > C, c.645_726del) in four of six fam-
ilies (Table 1; Fig. 1b). Both of these two novel mutations
occurred within the highly conserved kinase domain of
STK11 (Fig. 2a, b). Mutation c.645_726del is de novo in
sporadic family 6 and c.752G > A and c.545 T > C co-
segregated with PJS in multiplex family 4 and 5, respect-
ively. The unaffected parents in sporadic family 2 with
c.721G > C were not be tested as DNA samples were not
available. The novel missense mutations (c.721G > C) re-
sults in the substitution of amino acid in codon 241
(p.Ala241Pro) and was predicted to be “probably dam-
aging” by PolyPhen-2 (Additional file 1: Figure S1). The
novel 82-base deletion mutation (c.645_726del) in exon
5 of the STK11 gene would cause a frameshift change at
codon 215, which would introduce a putative stop at
codon 259 (p.Gly215GlyfsX45) with partial loss of the
kinase domain and complete loss of the C-terminal of
the a-helix (Fig. 2c).
Using MLPA analysis, two gross deletions del (exon1)
and del(2–5) in the STK11 gene were detected in the
remaining two families (Fig. 1c). Deletion of exon 1
detected in patient 101 has been previously reported
Table 1 STK11 gene mutations and Clinical characteristics of patients with Peutz-Jeghers syndrome
Family Patient Exon Nucleotide
change












1 101 1 Del(exon1) M 24 No Yes colon hamartomas 10 Yes No adenoma
2 201 5 c.721G > Ca F 16 No Yes NA NA NA NA NA NA
3 301 2-5 Del(exon2-5)a M 13 Yes Yes Small bowel,
colon
hamartomas 7 No Yes No
302 2-5 Del(exon2-5)a M 38 Yes Yes NA NA NA No No No
4 401 6 c.752G > A M 30 Yes Yes Gastric, colon hamartomas 22 No No No
5 501 4 c.545 T > C M 7 Yes Yes Gastric, colon hamartomas 7 No No No
503 4 c.545 T > C F 45 Yes Yes NA NA NA No No No
6 601 5 c.645_726dela M 9 No Yes gastric hamartomas 8 Yes No No
F female, M male, NA no available, MP mucocutaneous pigmentation, FPA the first polypectomy age
anovel mutations
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and is de novo in sporadic family 1. The gross dele-
tion of exon 2–5 found in patient 301 and patient
302 was not found in unaffected members in multi-
plex family 3, which, as well as novel mutations de-
tected by direct sequencing (c.721G > C and
c.645_726del), has not been previously reported in the
Human Gene Mutation Database (HGMD), Leiden
Open Variation Database (LOVD), NCBI-dbSNP, or
Exome Variant Server (EVS). All six variants were not
detected in the 100 unrelated normal controls.
Discussion
Currently, 396 mutations in the STK11 gene have been
detected in patients with PJS or other disorders (HGMD
Professional 2016.2), including missense/nonsense muta-
tions (29.8 %), small deletions/insertions/indels (38.9 %),
gross deletions/insertions/duplications (20.5 %), splice-
site mutations (9.8 %), and complex rearrangements
(1.0 %). Many mutations would influence kinase activity
of the STK11 protein by preventing it from binding with
MO25 and STRAD [10]. STK11 (+/−) mice in previous
studies were found to develop gastrointestinal hamarto-
matous polyposis, suggesting that haploinsufficiency of
STK11 is a mechanism of PJS [11].
In the present study, among the six mutations detected
in six families with PJS, del(exon1) in family 1, c.752G >A
in family 4, and c.545 T > C in family 5 have been previ-
ously reported [7, 12, 13]. In family 2, novel missense mu-
tation c.721G > C was detected. Its mutant residue
p.Ala241Pro is close to previously identified PJS-causing
mutations c.724G > T (p.Gly242Trp) and c.751G >A
(p.Gly251Ser), affecting highly conserved residues [12, 14].
The residue altered by p.Ala241Pro are located in the kin-
ase core domain, in which mutations would lead to a loss
of the kinase activity and disrupt the function of the
STK11 protein, indicating that p.Ala241Pro is most likely
disease-causing [15]. In addition, a prediction from
PolyPhen-2 online software strongly suggested that it is a
pathogenic mutation. Patient 601 in family 6 with typical
PJS phenotype carried a novel frameshift mutation
Fig. 1 a Pedigrees of family 3, 4 and 5 with PJS showed a autosomal dominant pattern and family 1, 2, and 6 were sporadic. b Sanger
sequencing showed four heterozygous mutations, c.721G > C, c.752G > A, c.545 T > C, and c.645_726del. c MLPA assay showed two heterozygous
gross deletions, del(exon1) and del(exon2-5)
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c.645_726del (p.Gly215GlyfsX45), which was predicted to
generate a prematurely terminated protein with a partial
loss of the kinase domain and a complete absence of the
C–terminal. Beyond a loss of kinase activity, the truncated
protein p.Gly215GlyfsX45 would impair STK11 polarizing
activity and the STK11-mediated activation of the AMPK
pathway [16]. Moreover, an absence of autophosphoryl-
ation and phosphorylation sites Thr336 and Ser428 would
disrupt the cell growth suppressive capacity of STK11 pro-
tein [5]. In family 3, a novel gross deletion of exon 2–5
were identified in patient 301 and 302. This deletion
would be pathogenic as deletions of exon 2–3 and exon
4–5 have been reported to cause a skip of partial exons
within the kinase domain [3, 17], which would destroy the
structure of STK11 protein and affect its stability by pre-
venting the binding of Hsp90 and Cdc37 [18]. The
mutations c.645_726del, del(exon1) and del(exon2–5), as
well as previous indentified PJS-causing deletions [7], fur-
ther demonstrates that haploinsufficiency of STK11 is a
mechanism of PJS [11].
In our study, the probands in these six families exhib-
ited the characteristic phenotypes of PJS, among which
patient 101, 301, and 601 had complications intussus-
ceptions and intestinal obstruction. As we know, the
relationship between the types and sites of variants in
STK11 and the phenotypes of PJS cases has been investi-
gated in several studies. On one hand, individuals with
missense mutations in STK11 typically have a later onset
for PJS symptoms [19], but have cancer risks similar to
the ones with truncating mutation [20]. In our study, the
patients carrying truncating mutations (patient 101, 301,
and 601) underwent the first polypectomy of GI polyps
Fig. 2 a The structure of STK11 gene. It contains a large kinase domain which spans from exon1 to exon 8. b Evolutionary conservation of amino
acid residues altered by c.721G > C (p.Ala241Pro) and c.645_726del (p.Gly215GlyfsX45) across different species. c The mutant protein
(p.Gly215GlyfsX45) was predicted to result in partial loss of the kinase domain and complete loss of the C-terminal domain of the a-helix by
Swiss-Model online software compared to the wild type. The blue Gly215 indicates the mutant site
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and related complications at earlier age (average age =
8.3, standard deviation = 1.2) than the ones with mis-
sense mutations (patient 401 and patient 501, average
age = 14.5, standard deviation = 7.5). Moreover, we found
that more individuals with truncating mutations under-
went severe complications than ones with missense mu-
tations, indicating that truncating mutations of STK11
may have a greater trend to result in severe complica-
tions in PJS patients. On the other hand, mutations in
exon 3 and exon 6 have been associated with a higher
cancer risk [20, 21]. In our study, since no cancer was
found in most of these patients, a clear genotype-
phenotype correction could not be established. However,
colon adenoma detected in patient 101 once again veri-
fied a previous reported pathway of hamartoma-(aden-
oma)-carcinoma in PJS patients [22].
Timely surveillance and early treatment for PJS pa-
tients are crucial to improve their quality of life. Current
surveillance protocols have two main purposes. One is
to detect sizeable GI polyps which could cause severe
complications and the other is to detect cancer at an
early stage [23]. The potential relationship between trun-
cating mutations of STK11 and severe complications dis-
covered in this study may help PJS patients improve the
quality of life by monitoring the development of GI
polyps at an earlier age or at shorter intervals.
Conclusions
In summary, three novel mutations and three recurrent
mutations in STK11 were identified in Chinese families
with PJS, which further broaden the mutation spectrum
of STK11. This potential relationship between truncating
mutations of STK11 and a higher risk of severe compli-
cations would help clinicians and genetic counselors to
provide better clinical services for PJS patients.
Additional file
Additional file 1: Figure S1. Polyphen-2 reports for the pathogenicity
of the mutant amino acid residues in STK11. The amino acid substitution
p.Ala241Pro was valued “PROBABLY DAMAGING” with the score 0.999
(HumDiv) and 0.971 (HumVar). (TIF 95 kb)
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